Cancel
Rasmus Holm-Jorgensen
Chief Financial Officer
@
Acrivon Therapeutics
7z5ftb2f6w4xy4p@5w2f53w.f79
Sign up to see email
See Linkedin
Known information
- Has over 25 years of experience building companies and driving strategy.
- Was part of the founding team of Kiniksa Pharmaceuticals and led the company through IPO and product launch.
- Expanded the portfolio of Synageva BioPharma as Group VP and General Manager, culminating in the company’s sale for $9 billion.
- Worked for 12 years at Novo Nordisk in the U.S., Europe, and LATAM with responsibilities for economy and planning, portfolio analysis, investor relations, and finance.
- Received an M.S. in Economics from Copenhagen University.
- Completed executive training at INSEAD, Stanford University, and Harvard Business School.
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information
